New Insights into Therapy for Alzheimer’s and Other Neurodegenerative Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 22 October 2024 | Viewed by 16135
Special Issue Editors
2. Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA
Interests: Alzheimer’s disease; aging; determinants of longevity; neurodegenerative diseases
Interests: drug screening in silico; protein-protein interactions; bioinformatics
2. Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA
Interests: Alzheimer’s disease; aging; determinants of longevity; neurodegenerative diseases; cardiovascular disease; cachexia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) features two diagnostic types of aggregate: extracellular Aβ amyloids, and intra-neuronal tau tangles. However, many other proteins have also been identified within AD aggregates and often feature AD-specific phosphorylations or other post-translational modifications [PTMs] 1,2. The upregulation of several kinases has been implicated as possibly driving AD pathology, but other PTMs (e.g., acetylation, oxidation, glycosylation) can also induce protein misfolding and aggregation. In this Special Issue of Pharmaceuticals, we welcome papers that describe research addressing any part of the progression from the identification of novel drug targets, the in silico screening of structural libraries, the validation of candidate molecules in cell or animal model systems, and ultimately culminating in human trials. The highest priority will be given to work presenting novel targets and evidence for their potential utility in preventing or ameliorating Alzheimer’s disease or other neurological diseases, and any other diseases where protein aggregation due to altered proteostasis is noted, and to the identification and validation of early biomarkers associated with cognitive impairment and its progression to AD.
1 Ganne, A., Balasubramaniam, M., Griffin, W. S. T., Shmookler Reis, R. J. & Ayyadevara, S. Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer's Disease. Pharmaceutics 14, doi:10.3390/pharmaceutics14071354 (2022).
2 Ayyadevara, S. et al. Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls. Aging Cell 15, 924-939, doi:10.1111/acel.12501 (2016).
Prof. Dr. Robert Joseph Shmookler Reis
Dr. Meenakshisundaram Balasubramaniam
Dr. Srinivas Ayyadevara
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
- amyotrophic lateral sclerosis
- neurodegeneration
- inflammation
- anti-inflammatory drugs
- post-translational modifications
- protein misfolding
- protein aggregation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.